Undisclosed autophagy-based degrader / Casma Therap - LARVOL DELTA

Casma Therapeutics Raises $46.0 M in Series C Funding (Businesswire) - "Casma Therapeutics, Inc....announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono Venture Investment. Current investors Eventide Asset Management, LLC, Schroders Capital, The Column Group, Third Rock Ventures, and other funds also participated in the financing. Dr. Hiromichi Kimura, Investment Director of Astellas Ventures, has joined the board of directors. Dr. Tomotaka Okino of Ono Venture Investment and Amgen Ventures have joined as board observers....Casma will use proceeds to advance its lead program for MYD88 mutant lymphoma through preclinical and into IND enabling studies."

Financing • Hematological Malignancies • Lymphoma • Oncology